Toshima Z. Parris
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer.
Journal: Epigenetics
Published: September 02, 2026
The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages.
Journal: NPJ precision oncology
Published: January 15, 2026
Retrospective study of comparable survival after neoadjuvant versus adjuvant chemotherapy in cT1-2N0M0 triple-negative breast cancer.
Journal: Breast cancer research and treatment
Published: November 24, 2025
Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study.
Journal: Breast cancer research and treatment
Published: September 26, 2025
Correction: Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence.
Journal: Breast cancer research and treatment
Published: September 26, 2025
Loss of hepatocyte PI3Kα reduces hepatocellular carcinoma and hepatocyte proliferation in association with altered lipid metabolism.
Journal: JHEP reports : innovation in hepatology
Published: September 11, 2025
Proteomic analysis of ovarian carcinoma reveals diagnostic and prognostic biomarkers with histotype- and stage-specificity.
Journal: Journal of ovarian research
Published: September 08, 2025
LMTK3 as a spatially regulated and stage-dependent biomarker in epithelial ovarian tumorigenesis.
Journal: Molecular therapy. Oncology
Published: August 27, 2025
Unveiling histotype-specific biomarkers in ovarian carcinoma using proteomics.
Journal: Molecular therapy. Oncology
Published: May 13, 2025
Last Updated: 09/26/2026